Based on these results, and those obtained by other authors (reviewed in [115]), anti-MOG antibodies would not be adequate biomarkers for the diagnosis or prognosis of MS, but rather for its differential diagnosis with MOG+-CNS demyelinating disease representing a new distinct disease entity. This evidence concerns the gene MOG and myeloid sarcoma.